Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis

Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis

Background and objective Epidermal growth factor receptor (EGFR) gene mutation is closely related to the EGFR-TKI target treatment and prognosis of lung adenocarcinoma patients. The mutation status of EGFR is limited by tissue detection. The purpose of this study was to investigate the difference of...

Full description

Bibliographic Details
Main Authors:	Fei SU, Ke ZHENG, Yiyun FU, Qian WU, Yuan TANG, Weiya WANG, Lili JIANG
Format:	Article
Language:	zho
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2018-05-01
Series:	Chinese Journal of Lung Cancer
Subjects:	Lung neoplasms Circulating cell-free DNA EGFR T790M Prognosis
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2018.05.06

Similar Items

Can CT Radiomics Detect Acquired T790M Mutation and Predict Prognosis in Advanced Lung Adenocarcinoma With Progression After First- or Second-Generation EGFR TKIs?
by: Xiaohuang Yang, et al.
Published: (2022-07-01)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
by: Chan Xiang, PhD, et al.
Published: (2021-07-01)

Sputum cell‐free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR‐TKIs
by: Zheng Wang, et al.
Published: (2021-05-01)

Profile of Exon 20 T790M Mutation Incidence Rate with Plasma ctDNA in Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment
by: Muhammad Harbi Praditya, et al.
Published: (2023-01-01)

Acquired Drug Resistance Mechanism of Osimertinib in the Targeted Therapy of Non-small Cell Lung Cancer
by: Zitong ZHAO, et al.
Published: (2020-04-01)

Real-world Treatment Patterns in Patients with EGFR Mutation-positive NSCLC Receiving a First-Line, First- or Second-generation EGFR Tyrosine Kinase Inhibitor in South Korea and Taiwan
by: Jae Cheol Lee, et al.
Published: (2021-05-01)

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)
by: Yvonne L. E. Ang, et al.
Published: (2023-10-01)

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors
by: Ikei S. Kobayashi, MD, PhD, et al.
Published: (2024-01-01)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
by: Yu Wang, et al.
Published: (2021-10-01)

Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients
by: Mariella Dono, et al.
Published: (2019-04-01)

Identification of Candidate Biomarkers for EGFR-T790M Drug-resistant  Gene Mutation in Advanced Lung Adenocarcinoma
by: Lijuan CHEN, et al.
Published: (2020-11-01)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: Are They Different from Those with Common <i>EGFR</i> Mutations?
by: Hyun Ae Jung, et al.
Published: (2020-10-01)

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
by: Gao X, et al.
Published: (2019-11-01)

Effects of EGFR Gene Polymorphisms on Efficacy and Prognosis  in Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs
by: Liangshan DA, et al.
Published: (2013-03-01)

Liquid Biopsy: A Multi-Parametric Analysis of Mutation Status, Circulating Tumor Cells and Inflammatory Markers in <i>EGFR</i>-Mutated NSCLC
by: Martin P. Barr, et al.
Published: (2022-09-01)

Higher osimertinib introduction rate achieved by multiple repeated rebiopsy after acquired resistance to first/second generation EGFR‐TKIs
by: Taira Ninomaru, et al.
Published: (2021-03-01)

Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA
by: Zhang R, et al.
Published: (2018-05-01)

The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma
by: Wensheng Zhou, et al.
Published: (2022-03-01)

Clinical impact of rebiopsy among patients with epidermal growth factor receptor‐mutant lung adenocarcinoma in a real‐world clinical setting
by: Yunha Nam, et al.
Published: (2021-03-01)

BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer
by: Fushun Fan, et al.
Published: (2021-02-01)

Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report
by: Diego Enrico, MD, et al.
Published: (2023-02-01)

Development of epidermal growth factor receptor tyrosine kinase inhibitors against EGFR T790M. Mutation in non small-cell lung carcinoma
by: Wang Yuli, et al.
Published: (2016-01-01)

A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients
by: Francesco Cortiula, et al.
Published: (2020-09-01)

Successful treatment of a patient with advanced lung adenocarcinoma (EGFR-T790M and C797S cis) with lazertinib: A case report and literature review
by: Yue Fang, et al.
Published: (2023-01-01)

Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma
by: Zheng H, et al.
Published: (2019-07-01)

The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare
by: Weiting Li, et al.
Published: (2022-07-01)

Integrated Omics Analysis of Non-Small-Cell Lung Cancer Cells Harboring the EGFR C797S Mutation Reveals the Potential of AXL as a Novel Therapeutic Target in TKI-Resistant Lung Cancer
by: Tong-Hong Wang, et al.
Published: (2020-12-01)

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
by: Thang Thanh Phan, et al.
Published: (2019-01-01)

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib
by: Atsushi Osoegawa, MD, PhD, et al.
Published: (2021-07-01)

Application of ddPCR in detection of the status and abundance of EGFR T790M mutation in the plasma samples of non-small cell lung cancer patients
by: Hui Zhang, et al.
Published: (2023-01-01)

Advanced Research on Non-small Cell Lung Cancer with De Novo T790M Mutation
by: Xin WANG, et al.
Published: (2019-05-01)

Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations
by: Yuichiro Takeda, et al.
Published: (2020-10-01)

EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation
by: Yang Chen, et al.
Published: (2018-03-01)

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
by: Xie Y, et al.
Published: (2021-10-01)

The prognosis of TP53 and EGFR co-mutation in patients with advanced lung adenocarcinoma and intracranial metastasis treated with EGFR-TKIs
by: Weiguo Gu, et al.
Published: (2024-02-01)

Clinical Characteristics and Outcomes of Lung Cancer Patients  with EGFR Mutations in Exons 19 and 21
by: Renwang LIU, et al.
Published: (2014-11-01)

Role of the Expression Level of Nrf2 in Predicting Response of EGFR-TKIs  in Lung Adenocarcinoma Patients with EGFR Gene Mutations
by: Xiang ZHU, et al.
Published: (2014-02-01)

Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
by: Changhui Li, et al.
Published: (2021-05-01)

Advances in the Treatment of EGFR Exon 20ins Mutant NSCLC
by: Meiyi XU, et al.
Published: (2023-02-01)

Real-World Evidence of EGFR Targeted Therapy in NSCLC– A Brief Report of Decade Long Single Center Experience
by: Anuradha Chougule, PhD, et al.
Published: (2023-11-01)